{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:11:36Z","timestamp":1793340696877,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1136\/ard-2024-225492","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T13:20:19Z","timestamp":1709040019000},"page":"687-695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct04232280","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05127434","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jin Kyun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2024-225492_bib1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","article-title":"The mortality of rheumatoid arthritis","volume":"37","author":"Wolfe","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225492_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrrheum.2014.206","article-title":"Vaccination of patients with autoimmune inflammatory rheumatic diseases","volume":"11","author":"Westra","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-225492_bib3","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/587063","article-title":"Vaccination in patients with chronic rheumatic or autoimmune diseases","volume":"46","author":"Gl\u00fcck","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1136\/ard-2024-225492_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225492_bib5","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1002\/art.42109","article-title":"American college of rheumatology guideline for Vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"74","author":"Curtis","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225492_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/acr.25241","article-title":"COVID-19 vaccine uptake, hesitancy, and flare in a large rheumatology practice network","volume":"76","author":"Holladay","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2024-225492_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/rheumatology\/keac305","article-title":"COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study","volume":"62","author":"Sen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225492_bib8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3899\/jrheum.220135","article-title":"Physician perspectives on vaccination in patients with autoimmune inflammatory rheumatic diseases: an international survey","volume":"50","author":"Seo","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-225492_bib9","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.vaccine.2015.01.065","article-title":"Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the International COMORA cohort","volume":"33","author":"Hmamouchi","year":"2015","journal-title":"Vaccine"},{"key":"10.1136\/ard-2024-225492_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153848","article-title":"Influenza and pneumococcal vaccination uptake in patients with rheumatoid arthritis treated with immunosuppressive therapy in the UK: a retrospective cohort study using data from the clinical practice research Datalink","volume":"11","author":"Costello","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1136\/ard-2024-225492_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in Vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1136\/ard-2024-225492_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1136\/ard-2024-225492_bib13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems Vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"10.1136\/ard-2024-225492_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-Biontech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2024-225492_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature09489","article-title":"2\u2032-O methylation of the viral mRNA cap evades host restriction by IFIT family members","volume":"468","author":"Daffis","year":"2010","journal-title":"Nature"},{"key":"10.1136\/ard-2024-225492_bib16","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.micinf.2006.02.028","article-title":"Retinoic acid inducible gene-I and Mda-5 are involved in influenza A virus-induced expression of antiviral Cytokines","volume":"8","author":"Sir\u00e9n","year":"2006","journal-title":"Microbes and Infection"},{"key":"10.1136\/ard-2024-225492_bib17","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"10.1136\/ard-2024-225492_bib18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1136\/ard-2024-225492_bib19","author":"Institutet TNAaK"},{"key":"10.1136\/ard-2024-225492_bib20","series-title":"Breaking Through: My Life In Science","author":"Karik\u00f3","year":"2023"},{"key":"10.1136\/ard-2024-225492_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-Methylpseudouridine-incorporated mRNA Outperforms Pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced Immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J Control Release"},{"key":"10.1136\/ard-2024-225492_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-042420-112725","article-title":"mRNA vaccines in the COVID-19 pandemic and beyond","volume":"73","author":"Hogan","year":"2022","journal-title":"Annu Rev Med"},{"key":"10.1136\/ard-2024-225492_bib23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1136\/ard-2024-225492_bib24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and Immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1136\/ard-2024-225492_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/vaccines9010065","article-title":"Nanomaterial delivery systems for mRNA vaccines","volume":"9","author":"Buschmann","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1136\/ard-2024-225492_bib26","first-page":"1","article-title":"Advisory Committee on immunization practices centers for disease C, prevention. prevention of herpes Zoster: recommendations of the advisory committee on immunization practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1136\/ard-2024-225492_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-225492_bib28","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/ard-2023-224449","article-title":"Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)","volume":"82","author":"Taylor","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225492_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","article-title":"A trans-amplifying RNA vaccine strategy for induction of potent protective immunity","volume":"28","author":"Beissert","year":"2020","journal-title":"Mol Ther"},{"key":"10.1136\/ard-2024-225492_bib30","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1056\/NEJMcibr2009737","article-title":"Amplifying RNA vaccine development","volume":"382","author":"Fuller","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225492_bib31","doi-asserted-by":"crossref","first-page":"24075","DOI":"10.1073\/pnas.1908052116","article-title":"mRNA structure regulates protein expression through changes in functional half-life","volume":"116","author":"Mauger","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ard-2024-225492_bib32","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against ad vectors: humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1136\/ard-2024-225492_bib33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"169","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1136\/ard-2024-225492_bib34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-bioeng-110220-031722","article-title":"Current developments and challenges of mRNA vaccines","volume":"24","author":"Chen","year":"2022","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1136\/ard-2024-225492_bib35","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.immuni.2022.05.007","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"55","author":"Alameh","year":"2022","journal-title":"Immunity"},{"key":"10.1136\/ard-2024-225492_bib36","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41590-022-01168-4","article-title":"Making innate sense of mRNA vaccine Adjuvanticity","volume":"23","author":"Kobiyama","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2024-225492_bib37","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225492_bib38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-Cov-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225492_bib39","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.2021.5374","article-title":"Reactogenicity following receipt of mRNA-based COVID-19 vaccines","volume":"325","author":"Chapin-Bardales","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/ard-2024-225492_bib40","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1136\/ard-2024-225492_bib41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new Coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1136\/ard-2024-225492_bib42","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-Cov-2","volume":"383","author":"Jackson","year":"2020","journal-title":"Preliminary Report N Engl J Med"},{"key":"10.1136\/ard-2024-225492_bib43","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41591-021-01560-x","article-title":"Boosting immunity to COVID-19 vaccines","volume":"27","author":"Juno","year":"2021","journal-title":"Nat Med"},{"key":"10.1136\/ard-2024-225492_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-Cov-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"10.1136\/ard-2024-225492_bib45","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S1473-3099(23)00373-0","article-title":"Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-Cov-2 infection and COVID-19-related hospital admission among SARS-Cov-2-naive and previously infected individuals: a retrospective cohort study","volume":"23","author":"Tan","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1136\/ard-2024-225492_bib46","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-Cov-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"Kurhade","year":"2023","journal-title":"Nat Med"},{"key":"10.1136\/ard-2024-225492_bib47","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.15585\/mmwr.mm7148e1","article-title":"Effectiveness of Bivalent mRNA vaccines in preventing symptomatic SARS-Cov-2 infection - increasing community access to testing program, United States, September-November 2022","volume":"71","author":"Link-Gelles","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1136\/ard-2024-225492_bib48","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/ard-2024-225492_bib49","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults","volume":"137","author":"McNeil","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2024-225492_bib50","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.anai.2021.05.011","article-title":"Primary care provider-reported prevalence of vaccine and polyethylene glycol allergy in Canada","volume":"127","author":"Abrams","year":"2021","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1136\/ard-2024-225492_bib51","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1136\/ard-2024-225492_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to pegylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1136\/ard-2024-225492_bib53","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225492_bib54","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/ard-2022-222682","article-title":"Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls","volume":"82","author":"Kartnig","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225492_bib55","article-title":"COVID-19 vaccine safety during pregnancy and Breastfeeding in women with autoimmune diseases: results from the COVAD study","author":"Andreoli","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225492_bib56","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/rheumatology\/keac624","article-title":"COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis","volume":"62","author":"Naveen","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225492_bib57","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1093\/rheumatology\/kead144","article-title":"Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period - a cross-sequential study based on COVAD surveys","volume":"62","author":"Jagtap","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225492_bib58","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.14961","article-title":"Flares of autoimmune rheumatic disease following COVID-19 infection: observations from the COVAD study","volume":"27","author":"Sandhu","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2024-225492_bib59","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/annrheumdis-2021-221490","article-title":"Safety of vaccination against SARS-Cov-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus vaccine (COVAX) physician-reported Registry","volume":"81","author":"Machado","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225492_bib60","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a Multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225492_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103340","article-title":"Insights into new-onset autoimmune diseases after COVID-19 vaccination","volume":"22","author":"Guo","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2024-225492_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.872683","article-title":"COVID-19 vaccination and the rate of immune and autoimmune adverse events following immunization: insights from a narrative literature review","volume":"13","author":"Mahroum","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-225492_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003022","article-title":"Inflammatory rheumatic diseases with onset after SARS-Cov-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group","volume":"9","author":"Ursini","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225492_bib64","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1007\/s10067-023-06692-8","article-title":"Correction to: incident autoimmune diseases in association with SARS-Cov-2 infection: A matched cohort study","volume":"42","author":"Tesch","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2024-225492_bib65","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.coviro.2014.02.008","article-title":"Production of live attenuated influenza vaccines against seasonal and potential pandemic influenza viruses","volume":"6","author":"Jin","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1136\/ard-2024-225492_bib66","author":"Prevention CfDCa"},{"key":"10.1136\/ard-2024-225492_bib67","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/infdis\/jiz433","article-title":"Evidence that blunted Cd4 T-cell responses underlie deficient protective antibody responses to influenza vaccines in repeatedly vaccinated human subjects","volume":"222","author":"Richards","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1136\/ard-2024-225492_bib68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-2600(22)00266-1","article-title":"Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis","volume":"11","author":"Jones-Gray","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2024-225492_bib69","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1164\/rccm.201411-1988OC","article-title":"Natural T cell-mediated protection against seasonal and pandemic influenza. results of the flu watch cohort study","volume":"191","author":"Hayward","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/ard-2024-225492_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2024-225492_bib71","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"10.1136\/ard-2024-225492_bib72","author":"Moderna"},{"key":"10.1136\/ard-2024-225492_bib73","author":"Moderna"},{"key":"10.1136\/ard-2024-225492_bib74","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225492_bib75","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.o2681","article-title":"US faces triple epidemic of flu, RSV, and Covid","author":"Tanne","year":"2022","journal-title":"BMJ"},{"key":"10.1136\/ard-2024-225492_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/srep34108","article-title":"Pre-fusion F is absent on the surface of formalin-Inactivated respiratory syncytial virus","volume":"6","author":"Killikelly","year":"2016","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2024-225492_bib77","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1136\/ard-2024-225492_bib78","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225492_bib79","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225492_bib80","author":"Precision Vaccinations"},{"key":"10.1136\/ard-2024-225492_bib81","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and Immunogenicity of an mRNA-based RSV Prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"Supplement_2","key":"10.1136\/ard-2024-225492_bib82","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.312","article-title":"234. safety and Immunogenicity of mRNA-1345, an mRNA-based RSV vaccine in younger and older adult cohorts: results from a phase 1, randomized clinical trial","volume":"9","author":"Chen","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1136\/ard-2024-225492_bib83","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV Pref vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225492_bib84","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes Zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225492_bib85","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes Zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225492_bib86","article-title":"Long-term protection against herpes zoster by the adjuvanted recombinant Zoster vaccine: interim efficacy, Immunogenicity, and safety results up to 10 years after initial vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1136\/ard-2024-225492_bib87","article-title":"Serologic immunogenicity and safety of herpes Zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors","author":"K\u00e4llmark","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225492_bib88","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1086\/649903","article-title":"Cytomegalovirus reinfections in healthy seroimmune women","volume":"201","author":"Ross","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1136\/ard-2024-225492_bib89","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/rmv.544","article-title":"New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection","volume":"17","author":"Dollard","year":"2007","journal-title":"Rev Med Virol"},{"key":"10.1136\/ard-2024-225492_bib90","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/09612033221074180","article-title":"Congenital cytomegalovirus infection after maternal primary infection in a patient with systemic lupus erythematosus: a case report and literature review","volume":"31","author":"Nakamura","year":"2022","journal-title":"Lupus"},{"key":"10.1136\/ard-2024-225492_bib91","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jmii.2018.12.002","article-title":"The clinical features and mortality risk factors of cytomegalovirus infection in patients with systemic lupus erythematosus","volume":"52","author":"Hung","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1136\/ard-2024-225492_bib92","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-023-00807-w","article-title":"Clinical phenotypes and prognosis of cytomegalovirus infection in the pediatric systemic lupus erythematosus: a longitudinal analysis","volume":"21","author":"Zhang","year":"2023","journal-title":"Pediatr Rheumatol"},{"key":"10.1136\/ard-2024-225492_bib93","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-Antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"issue":"Supplement_2","key":"10.1136\/ard-2024-225492_bib94","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.190","article-title":"112. interim results from a phase 2, randomized, observer-blind, placebo-controlled, dose-finding trial of an mRNA-based cytomegalovirus vaccine in healthy adults","volume":"9","author":"Panther","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1136\/ard-2024-225492_bib95","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225492_bib96","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMcp1001116","article-title":"Infectious mononucleosis","volume":"362","author":"Luzuriaga","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225492_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212676","article-title":"Risk factors for multiple sclerosis in the context of Epstein-Barr virus infection","volume":"14","author":"Hedstr\u00f6m","year":"2023","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-225492_bib98","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41541-022-00587-6","article-title":"Urgency and necessity of Epstein-Barr virus prophylactic vaccines","volume":"7","author":"Zhong","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1136\/ard-2024-225492_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.734471","article-title":"Epstein Barr virus: development of vaccines and immune cell therapy for EBV-associated diseases","volume":"12","author":"Cui","year":"2021","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-225492_bib100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A Noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"key":"10.1136\/ard-2024-225492_bib101","article-title":"Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-225492_bib102","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/v14020401","article-title":"mRNA vaccine development for emerging animal and Zoonotic diseases","volume":"14","author":"Le","year":"2022","journal-title":"Viruses"},{"key":"10.1136\/ard-2024-225492_bib103","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724001249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724001249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2024-225492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T05:19:22Z","timestamp":1749791962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724001249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":103,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0003496724001249"],"URL":"https:\/\/doi.org\/10.1136\/ard-2024-225492","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-225492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}